Abbott Laboratories (ABT) Depreciation & Amortization (CF) (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $381.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 13.39% year-over-year to $381.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 10.13% YoY), and the FY2025 full-year result was $1.4 billion, up 7.01% from the prior year.
• Depreciation & Amortization (CF) climbed to $381.0 million in Q1 2026, from $370.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $381.0 million in Q1 2026 to a low of $302.0 million in Q2 2023.
• A 5-year average of $334.5 million and a median of $332.0 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) slipped 26.82% in 2022 and climbed 13.39% in 2026, its largest moves.
• Tracing ABT's Depreciation & Amortization (CF) over 5 years: stood at $311.0 million in 2022, then gained by 6.75% to $332.0 million in 2023, then increased by 3.01% to $342.0 million in 2024, then gained by 8.19% to $370.0 million in 2025, then climbed by 2.97% to $381.0 million in 2026.
• Business Quant data shows ABT's Depreciation & Amortization (CF) at $381.0 million in Q1 2026, $370.0 million in Q4 2025, and $371.0 million in Q3 2025.